Bahlis NJ et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: Results from cohort a of the MagnetisMM-3 study. ASH 2022;Abstract 391.

Carlo-Stella C et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. ASH 2022;Abstract 161.

Chari A et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 2022;387(24):2232-44. Abstract

Cohen YC et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8002.

Dholaria BR et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRiMM-2 results. ASCO 2023;Abstract 8003.

Lee HC et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. ASCO 2023;Abstract 8006.

Lesokhin AM et al. Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed/refractory multiple myeloma: Early experience from a phase I study. ASH 2022;Abstract 4415.

Mohty M et al. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma: Extended follow up and biweekly administration from MAGNETISMM-3. EHA 2023;Abstract S196.

Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract

Nooka AK et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. ASCO 2023;Abstract 8008.

Touzeau C et al. Evaluating teclistamab in patients with relapsed/refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents. EHA 2022;Abstract S184.

Wong SW et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Latest results from a phase 1 first-in-human clinical study. EHA 2023;Abstract P883.

Usmani SZ et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398(10301):665-74. Abstract

Van de Donk NWCJ et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8011.

Voorhees PM et al. A phase 1 first-in-human study of Abbv-383, a BCMA × CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma. ASH 2022;Abstract 4401.